A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

PURPOSE: This is the first study to compare the pharmacokinetics of QL1101, a proposed bevacizumab biosimilar, with Avastin(®) sourced from Roche Diagnostics GmbH. METHODS: In this double-blind, single-dose, parallel-group study, healthy male subjects were randomized 1:1 to receive QL1101 or Avastin...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ya-nan, Huang, Jie, Guo, Can, Yang, Shuang, Ye, Ling, Wu, Shu-ting, Zhang, Xing-fei, Yang, Xiao-yan, Han, Cui-cui, Pei, Qi, Huang, Lu, He, Qing-nan, Yang, Guo-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036053/
https://www.ncbi.nlm.nih.gov/pubmed/31907645
http://dx.doi.org/10.1007/s00280-019-04014-x

Ejemplares similares

Ejemplares similares